Amidst a pipeline bulging with oncology bets, GlaxoSmithKline has invested $120 million in a new biologics plant. The announcement was made by Emma Walmsley, CEO, at the drugmaker’s manufacturing site at Upper Merion, Pennsylvania. According to her, the investment will support and accelerate the transformation of GSK’s pipeline to deliver the next generation of medicines and vaccines.
GSK has invested almost $400 million in vaccines and specialty drugs across its US manufacturing network. The company has also put in place a deal to make its chickenpox vaccine in Russia. This comes at a time when GSK is pushing its vaccine portfolio abroad.
